Home General Biotechnology Drug Patent Expirations in January 2014

Drug Patent Expirations in January 2014

Drug Patent Expirations for January 2014

TradenameApplicantGeneric NamePatent NumberPatent Expiration
EPIVIR-HBVGlaxosmithklinelamivudineRE39155*PEDJan 2, 2014
MICARDISBoehringer Ingelheimtelmisartan5,591,762Jan 7, 2014
TWYNSTABoehringer Ingelheimamlodipine besylate; telmisartan5,591,762Jan 7, 2014
COMBIPATCHNovartisestradiol; norethindrone acetate6,024,976Jan 7, 2014
GLUCOTROL XLPfizerglipizide5,591,454Jan 7, 2014
VIVELLE-DOTNovartisestradiol6,024,976Jan 7, 2014
MICARDIS HCTBoehringer Ingelheimhydrochlorothiazide; telmisartan5,591,762Jan 7, 2014
RAPAMUNEPf Prism Cvsirolimus5,100,899*PEDJan 7, 2014
MINIVELLENovenestradiol6,024,976Jan 7, 2014
ATACANDAstrazenecacandesartan cilexetil5,534,534*PEDJan 9, 2014
ATACAND HCTAstrazenecacandesartan cilexetil; hydrochlorothiazide5,534,534*PEDJan 9, 2014
PRECEDEXHospiradexmedetomidine hydrochloride4,910,214*PEDJan 15, 2014
SANDOSTATIN LARNovartisoctreotide acetate5,538,739*PEDJan 23, 2014
XYZALUcb Inclevocetirizine dihydrochloride5,698,558*PEDJan 26, 2014
DULERAMerck Sharp Dohmeformoterol fumarate; mometasone furoate6,677,323Jan 27, 2014
NORVIRAbbottritonavir5,541,206*PEDJan 30, 2014
NORVIRAbbvieritonavir5,635,523*PEDJan 30, 2014
KALETRAAbbvielopinavir; ritonavir5,541,206*PEDJan 30, 2014
NORVIRAbbvieritonavir5,541,206*PEDJan 30, 2014
NORVIRAbbvieritonavir5,674,882*PEDJan 30, 2014
BETAXONAlcon Pharms Ltdlevobetaxolol hydrochloride5,540,918*PEDJan 30, 2014
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.